Holen Sie sich die Stockscreener-App
1.96
5.77%
-0.12
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
What analysts say about Aprea Therapeutics Inc. stockOverwhelming profit margins - jammulinksnews.com
Aprea Therapeutics Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional
Is Aprea Therapeutics Inc. a good long term investmentLightning-fast growth - jammulinksnews.com
What drives Aprea Therapeutics Inc. stock priceUnmatched profit potential - Autocar Professional
Franklin Covey Co. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
What analysts say about AMBO stockExplosive earning power - Jammu Links News
Why Aprea Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Courses - Newser
What makes Aprea Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser
How Rocky Mountain Chocolate Factory Inc. stock performs during market volatilityFree Consultation - Newser
How Aprea Therapeutics Inc. stock performs during market volatilityConsistent High Return Strategy - Newser
Aprea Therapeutics Insiders Still US$86k Away From Original Investment Value - simplywall.st
Aprea Therapeutics (NASDAQ:APRE) Trading 4.4% Higher – What’s Next? - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers - MSN
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News - GuruFocus
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - Morningstar
Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
CoreWeave Stock Skyrockets 137% In A Month: Hold Or Fold? - Barchart.com
Block Inc. Has Unusual Put Option ActivityShowing Bullish XYZ Investors - Barchart.com
Ostara Inc. Launches CG P2X In Western Canada: Phosphorus, Perfected - Barchart.com
Stocks In Play: WSP Global Inc. - Barchart.com
Alzheimer’s Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Dry Eye Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - Barchart.com
Supporting 2SLGBTQI+ Communities For A Safer, More Equitable And Inclusive Canada - Barchart.com
Artios' AACR Data Success: What It Means For Aprea Therapeutics' ATRN-119 Program - Barchart.com
REKO INTERNATIONAL GROUP INC. TO BUY BACK UP TO 276,066 OF ITS COMMON SHARES - Barchart.com
Aprea Therapeutics Confirms Directors and Accounting Firm - TipRanks
Stocks Finish Sharply Higher On A Resilient US Labor Market - Barchart.com
Compass Refresh, Inc. Launches New Headquarters in Sulphur Springs, TX – Bringing High-Quality Exterior Maintenance Across the Southern Region - Barchart.com
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Stocks In Play: Aimia Inc. - Barchart.com
4.56%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):